Related content

The novel dual PI3K/mTOR inhibitor GDC-0941 synergizes with the MEK inhibitor U0126 in non-small cell lung cancer cells

By            

Molecular Medicine Reports, Vol. 5, Iss. 2, 2012-01 ,pp. : 503-508

Spandidos Publications

Access to resources Recommend Favorite

GDC-0152 attenuates the malignant progression of osteosarcoma promoted by ANGPTL2 via PI3K/AKT but not p38MAPK signaling pathway

By                

International Journal of Oncology, Vol. 46, Iss. 4, 2015-01 ,pp. : 1651-1658

Spandidos Publications

Access to resources Recommend Favorite

HS-104, a PI3K inhibitor, enhances the anticancer efficacy of gemcitabine in pancreatic cancer

By              

International Journal of Oncology, Vol. 45, Iss. 1, 2014-01 ,pp. : 311-321

Spandidos Publications

Access to resources Recommend Favorite

Patient-derived xenografts reveal limits to PI3K/mTOR- and MEK-mediated inhibition of bladder cancer

By Cirone Pasquale   Andresen Catharine   Eswaraka Jeetendra   Lappin Patrick   Bagi Cedo  

Cancer Chemotherapy and Pharmacology, Vol. 73, Iss. 3, 2014-03 ,pp. : 525-538

Springer Publishing Company

Access to resources Recommend Favorite

Pharmacodynamic and toxicokinetic evaluation of the novel MEK inhibitor, PD0325901, in the rat following oral and intravenous administration

By Brown Alan   Carlson Tage   Loi Cho-Ming   Graziano Michael  

Cancer Chemotherapy and Pharmacology, Vol. 59, Iss. 5, 2007-04 ,pp. : 671-679

Springer Publishing Company

Access to resources Recommend Favorite